Market Overview

RBC: Neos Therapeutics Has 70% Upside, $500 Million Opportunity

Share:

RBC Capital Markets analyst Randall Stanicky initiated Neos Therapeutics Inc (NASDAQ: NEOS) at an Outperform with a $35 price target – 70 percent above Friday's $20.63 closing price.

Stanicky pointed to "bullish feedback from our physician survey" that suggests that the three late-stage treatments for ADHD could drive $500 million in peak sales. Neos' ADHD treatments are either orally disintegrating tablets (ODT) or liquid suspension treatments, which should serve ADHD's large pediatric/adolescent population well, RBC said. In fact, in RBC's physician survey, nearly half of physicians said that an ODT would be their "No. 1 treatment preference if available."

The first treatment could be approved as early as November 9, the note said. This gives the stock a near-term catalyst that could propel it higher. At the same time, FDA approval – if it happened – would further validate Neos' ODT and liquid suspension technologies. Beyond ADHD, RBC said that Neos should have the opportunity to apply those technologies more broadly with a potential new pipeline announced by year-end.

On the downside, RBC said that a bearish scenario could see the price could slip to $8. Risks to the $35 price target are regulatory risks given the company's late-stage products, increased generic competition, and litigation risks.

Since its IPO in mid-July, Neos has gained 5.6 percent. The company hit a high of $23.99 and a low of $17.10 during this time.

Latest Ratings for NEOS

DateFirmActionFromTo
Aug 2019MaintainsMarket Perform
Nov 2018MaintainsMarket OutperformMarket Outperform
Aug 2018MaintainsOutperformOutperform

View More Analyst Ratings for NEOS
View the Latest Analyst Ratings

Posted-In: Neos Therapeutics Randall Stanicky RBC Capital MarketsAnalyst Color Biotech Initiation Analyst Ratings General

 

Related Articles (NEOS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NVDACascendMaintains240.0
NXTCBank of AmericaReiterates89.0
RNRJP MorganAssumes173.0
CARBNorthlandDowngrades23.0
GLIBACitiUpgrades80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Benzinga's Top Downgrades

Morning Market Losers